Literature DB >> 9629847

Hereditary form of parkinsonism--dementia.

M D Muenter1, L S Forno, O Hornykiewicz, S J Kish, D M Maraganore, R J Caselli, H Okazaki, F M Howard, B J Snow, D B Calne.   

Abstract

In four generations of a family, 13 members were afflicted with an autosomal dominant disorder characterized by young age at onset, early weight loss, and rapidly progressive dopa-responsive parkinsonism, followed later by dementia and, in some, by hypotension. Intellectual dysfunction began with subjective memory loss and objective visuospatial dysfunction and was followed later by decline of frontal lobe cognitive and memory functions. Neuropathological examination in 4 autopsied cases showed neuronal loss in the substantia nigra and locus ceruleus and widespread Lewy bodies, many of them in the cerebral cortex; those in the hypothalamus and locus ceruleus were often of bizarre shapes. Other findings were vacuolation of the temporal cortex, unusual neuronal loss and gliosis in the hippocampus (CA 2/3), and neuronal loss in the nucleus basalis. There were no neuritic plaques, neurofibrillary tangles, or amyloid deposits. Positron emission tomography in 3 patients showed decreased striatal uptake of fluorodopa. Neurochemical analysis of an autopsied brain showed a pronounced decrease in choline acetyltransferase activity in the frontal and temporal cortices and hippocampus and a severe depletion of striatal dopamine with a pattern not typical of classic Parkinson's disease.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9629847     DOI: 10.1002/ana.410430612

Source DB:  PubMed          Journal:  Ann Neurol        ISSN: 0364-5134            Impact factor:   10.422


  41 in total

Review 1.  Rare genetic mutations shed light on the pathogenesis of Parkinson disease.

Authors:  Ted M Dawson; Valina L Dawson
Journal:  J Clin Invest       Date:  2003-01       Impact factor: 14.808

2.  Multisystem Lewy body disease and the other parkinsonian disorders.

Authors:  J William Langston; Birgitt Schüle; Linda Rees; R Jeremy Nichols; Carrolee Barlow
Journal:  Nat Genet       Date:  2015-12       Impact factor: 38.330

Review 3.  The neurobiological basis of cognitive impairment in Parkinson's disease.

Authors:  Glenda M Halliday; James B Leverenz; Jay S Schneider; Charles H Adler
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

Review 4.  Neuropathology of genetic synucleinopathies with parkinsonism: Review of the literature.

Authors:  Susanne A Schneider; Roy N Alcalay
Journal:  Mov Disord       Date:  2017-11       Impact factor: 10.338

5.  Multiplication of the alpha-synuclein gene is not a common disease mechanism in Lewy body disease.

Authors:  Paul J Lockhart; Jennifer Kachergus; Sarah Lincoln; Mary Hulihan; Gina Bisceglio; Natalie Thomas; Dennis Dickson; Matthew J Farrer
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

6.  Doublecortin-like Kinase 1 Regulates α-Synuclein Levels and Toxicity.

Authors:  Gabriel E Vázquez-Vélez; Kristyn A Gonzales; Jean-Pierre Revelli; Carolyn J Adamski; Fatemeh Alavi Naini; Aleksandar Bajić; Evelyn Craigen; Ronald Richman; Sabrina M Heman-Ackah; Matthew J A Wood; Maxime W C Rousseaux; Huda Y Zoghbi
Journal:  J Neurosci       Date:  2019-11-20       Impact factor: 6.167

7.  Familial dementia with Lewy bodies with an atypical clinical presentation.

Authors:  Lauren T Bonner; Debby W Tsuang; Monique M Cherrier; Charisma J Eugenio; Q Du Jennifer; Ellen J Steinbart; Pornprot Limprasert; Albert R La Spada; Benjamin Seltzer; Thomas D Bird; James B Leverenz
Journal:  J Geriatr Psychiatry Neurol       Date:  2003-03       Impact factor: 2.680

Review 8.  Parkinson's disease.

Authors:  Timothy R Mhyre; James T Boyd; Robert W Hamill; Kathleen A Maguire-Zeiss
Journal:  Subcell Biochem       Date:  2012

9.  Genetic neuropathology of Parkinson's disease.

Authors:  Mark R Cookson; John Hardy; Patrick A Lewis
Journal:  Int J Clin Exp Pathol       Date:  2008-01-01

10.  Targeting the progression of Parkinson's disease.

Authors:  J L George; S Mok; D Moses; S Wilkins; A I Bush; R A Cherny; D I Finkelstein
Journal:  Curr Neuropharmacol       Date:  2009-03       Impact factor: 7.363

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.